David Sallman, MD

Articles

Dr. Sallman on the Novel Menin Inhibitor KO-539 in AML

May 31st 2022

David Sallman, MD, discusses the background of the menin inhibitor, KO-539, in acute myeloid leukemia.

Dr. Sallman on the Examination of Magrolimab in AML

March 30th 2022

David Sallman, MD, discusses the examination of magrolimab in acute myeloid leukemia.

Dr. Sallman on the Role of Uproleselan in Targeting E-Selectin in AML

March 16th 2022

David Sallman, MD, discusses the role of uproleselan (GMI-1271) when utilized in acute myeloid leukemia.

Dr. Sallman on the Responses to PRGN-3006 in Select AML and Higher-Risk MDS

January 10th 2022

David Sallman, MD, discusses responses achieved a first-in-human dose escalation/dose expansion phase 1/1b clinical trial of an UltraCAR-T agent, PRGN-3006, in patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome with hypomethylating agent failure.

Dr. Sallman on the Efficacy of Pevonedistat Plus Azacitidine in Higher-Risk MDS

July 21st 2021

David Sallman, MD, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome.

Dr. Sallman on Unmet Treatment Needs in Higher-Risk MDS

July 12th 2021

David Sallman, MD, discusses unmet needs in the treatment of patients with higher-risk myelodysplastic syndromes.

Dr. Sallman on APR-246 Plus Azacitidine in TP53-Mutant MDS and AML

June 17th 2018

David Sallman, MD, assistant member, Moffitt Cancer Center, discusses the combination of APR-246 and azacitidine as a treatment for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.